
Feb 24 (Reuters) - Novo Nordisk A/S NOVOb.CO:
NOVO NORDISK ANNOUNCES SIGNIFICANT REDUCTION IN US LIST PRICE FOR WEGOVY®, OZEMPIC®, AND RYBELSUS® (SEMAGLUTIDE MEDICINES), BUILDING ON CONTINUED EFFORTS TO EXPAND ACCESS
NEW, LOWER LIST PRICE OF $675 PER MONTH ACROSS WEGOVY(®), OZEMPIC(®), AND RYBELSUS(®), EFFECTIVE JANUARY 1, 2027
THESE CHANGES IN LIST PRICE DO NOT HAVE AN IMPACT ON DIRECT-TO-PATIENT, SELF-PAY PRICES
DECISION APPLIES TO ALL DOSES OF THESE MEDICINES
Further company coverage: [NOVOb.CO]